Adial Pharmaceuticals

Advancing addiction treatment with innovative medications and groundbreaking clinical trials in the United States

Founded 2010 11-50 employees Post-IPO Equity Total: $30.22M Biotechnology, Health Care +1

Adial Pharmaceuticals is a biotechnology startup that is making waves in the United States with its groundbreaking approach to addiction treatment. The company's slogan, "Advancing addiction treatment with innovative medications and groundbreaking clinical trials in the United States," encapsulates its core mission. Founded in 2010, Adial Pharmaceuticals' focus lies in developing prescription treatments for addiction and related disorders, operating within the Biotechnology, Health Care, and Pharmaceutical industries. One of the key highlights of Adial Pharmaceuticals is its research on AD04, a compound that has completed the Phase IIb study for treating alcohol use disorders. Additionally, the company has made significant strides with AD01, which has completed Phase I clinical trials aimed at addressing addictive behaviors. In March 2024, Adial Pharmaceuticals secured a noteworthy $3.53M post-IPO equity investment, signifying confidence from investors in the company's potential and direction. This capital injection is poised to propel the company's innovative medications and clinical trial advancements to new heights, further cementing its position as a frontrunner in the addiction treatment space. With such a compelling vision and ongoing progress, Adial Pharmaceuticals stands as an intriguing venture for potential venture capital investment.

Funding Stage	Amount	Investors	Lead Investors	Date
Post IPO Equity	$3.53M	-		02 Mar 2024
Post IPO Equity	$4.00M	-		20 Oct 2023
Post IPO Equity	$750.00K	-		24 Feb 2023
Post IPO Equity	$10.00M	-		16 Feb 2022
Post IPO Equity	$5.00M	3	Keystone Capital Partners, Richard Gilliam +1	07 Jul 2021
Post IPO Equity	$2.10M	1	Keystone Capital Partners	15 Mar 2021
Post IPO Debt	$1.43M	-		26 Feb 2021
Post IPO Equity	$500.00K	-		25 Sep 2020
Debt Financing	$287.50K	-		15 May 2017
Venture Round	$2.63M	-		02 Oct 2013

Funding Stage

Amount

Investors

Lead Investors

Date

Post IPO Equity

$3.53M

02 Mar 2024

Post IPO Equity

$4.00M

20 Oct 2023

Post IPO Equity

$750.00K

24 Feb 2023

Post IPO Equity

$10.00M

16 Feb 2022

Post IPO Equity

$5.00M

Keystone Capital Partners, Richard Gilliam +1

07 Jul 2021

Post IPO Equity

$2.10M

Keystone Capital Partners

15 Mar 2021

Post IPO Debt

$1.43M

26 Feb 2021

Post IPO Equity

$500.00K

25 Sep 2020

Debt Financing

$287.50K

15 May 2017

Venture Round

$2.63M

02 Oct 2013

FAQ About Adial Pharmaceuticals

Advancing addiction treatment with innovative medications and groundbreaking clinical trials in the United States

Adial Pharmaceuticals was founded in 2010.

Adial Pharmaceuticals operates in Biotechnology, Health Care and Pharmaceutical. Its work centres on pharmaceuticals, drug development, clinical trials and addiction treatment.

Adial Pharmaceuticals has approximately 11-50 employees.

Adial Pharmaceuticals has completed 10 funding rounds, raising a total of $30.22M. The latest funding stage is Post-IPO Equity.

Top alternatives and competitors to Adial Pharmaceuticals include Trimel Pharmaceuticals, InterveXion Therapeutics, Idenix Pharmaceuticals, Anthera Pharmaceuticals, BioCorRx Pharmaceuticals Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Adial Pharmaceuticals and Trimel Pharmaceuticals are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About Adial Pharmaceuticals

Funding Rounds & Investors (10)

Adial Pharmaceuticals Alternatives & Competitors

FAQ About Adial Pharmaceuticals